Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 4
2011 1
2012 2
2013 3
2014 11
2015 21
2016 11
2017 8
2018 22
2019 12
2020 16
2021 13
2022 11
2023 12
2024 16
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Results by year

Filters applied: . Clear all
Page 1
Primary Central Nervous System Lymphoma Tumor Biopsies Show Heterogeneity in Gene Expression Profiles, Genetic Subtypes, and in vitro Drug Sensitivity to Kinase Inhibitors.
Zhu YX, Wong JC, Hilal T, Maguire A, Ocal J, Zellner K, Chen X, Link BK, Habermann TM, Maurer MJ, Cerhan JR, Johnston PB, Feldman AL, Scott DW, Rosenthal A, Rimsza L. Zhu YX, et al. Among authors: hilal t. medRxiv [Preprint]. 2024 Dec 6:2024.11.11.24316310. doi: 10.1101/2024.11.11.24316310. medRxiv. 2024. PMID: 39677423 Free PMC article. Preprint.
Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era.
Hampel PJ, Rabe KG, Wang Y, Hwang SR, Kenderian SS, Muchtar E, Leis JF, Koehler AB, Tsang M, Hilal T, Parrondo R, Bailen RJ, Schwager SM, Hanson CA, Braggio E, Slager SL, Shi M, Zepeda-Mendoza CJ, Van Dyke DL, Shanafelt TD, King RL, Call TG, Kay NE, Ding W, Parikh SA. Hampel PJ, et al. Among authors: hilal t. Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02492-4. Online ahead of print. Leukemia. 2024. PMID: 39658628 No abstract available.
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L; ROCCA Consortium. Roloff GW, et al. Among authors: hilal t. J Clin Oncol. 2024 Oct 17:JCO2400321. doi: 10.1200/JCO.24.00321. Online ahead of print. J Clin Oncol. 2024. PMID: 39418622
Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism.
Koehler AB, Rabe KG, Crusan DJ, Call TG, Achenbach SJ, Hampel PJ, Kenderian SS, Leis JF, Wang Y, Muchtar E, Tsang M, Hilal T, Parrondo R, Bailey KR, Ding W, Bailen R, Schwager SM, Shi M, Hanson CA, Slager SL, Kay NE, Ashrani AA, Parikh SA. Koehler AB, et al. Among authors: hilal t. J Thromb Haemost. 2025 Jan;23(1):149-157. doi: 10.1016/j.jtha.2024.08.029. Epub 2024 Sep 27. J Thromb Haemost. 2025. PMID: 39343103
The prion-like protein Doppel: A soluble biomarker steering ovarian cancer's peritoneal to circulatory dissemination.
Azam Z, Zhang X, Wahab R, Hasan MM, Kang B, Hassan MM, Karim M, Choi JU, Rana M, Zhang JY, Roy S, Byun Y, Kim IS, Song JY, Alam F, Toy EP, Reddy SY, Al-Hilal TA. Azam Z, et al. Among authors: al hilal ta. bioRxiv [Preprint]. 2024 Jul 29:2024.07.26.605386. doi: 10.1101/2024.07.26.605386. bioRxiv. 2024. PMID: 39211186 Free PMC article. Preprint.
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Aldoss I, Roloff GW, Faramand R, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Zhang A, Miller K, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Dholaria B, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Logan AC, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine J, Solh MM, Lee CJ, Kota VK, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat V, Shah BD, Muffly LS. Aldoss I, et al. Among authors: hilal t. Blood Adv. 2024 Dec 10;8(23):6139-6147. doi: 10.1182/bloodadvances.2024013747. Blood Adv. 2024. PMID: 39093952 Free PMC article.
IgG replacement in multiple myeloma.
Wonnaparhown A, Hilal T, Squire J, Freeman C, Fonseca R. Wonnaparhown A, et al. Among authors: hilal t. Blood Cancer J. 2024 Jul 25;14(1):124. doi: 10.1038/s41408-024-01107-6. Blood Cancer J. 2024. PMID: 39054331 Free PMC article. Review.
146 results